Fell Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$911K Sell
5,775
-300
-5% -$47.4K 0.78% 37
2026
Q2
$961K Sell
6,075
-25
-0.4% -$3.38K 0.81% 36
2026
Q1
$779K Hold
6,100
– – 0.74% 43
2025
Q4
$744K Buy
+6,100
New +$699K 0.73% 46

Other funds holding XBI

Fell Capital Management's XBI Position: Q3 2026 in Review

Fell Capital Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 4.9% in Q3 2026, selling an estimated $47.4K and leaving 5,775 shares worth $911K. The position accounts for 0.78% of the portfolio, ranked #37.

Fell Capital Management first reported a position in XBI in Q4 2025 and has held it in 4 quarters since. The position peaked at $961K in Q2 2026. 39 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

  • Fell Capital Management held 5,775 shares of State Street SPDR S&P Biotech ETF worth $911K as of Q3 2026.
  • Fell Capital Management sold 300 State Street SPDR S&P Biotech ETF shares in Q3 2026, an estimated $47.4K.
  • State Street SPDR S&P Biotech ETF made up 0.78% of Fell Capital Management's portfolio in Q3 2026, its #37 holding.
  • Fell Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and has held it in 4 quarters since.
  • Fell Capital Management's State Street SPDR S&P Biotech ETF position peaked at $961K in Q2 2026.
  • 39 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Fell Capital Management's 13F filing for Q3 2026, filed 9 Oct 2026.